Compare Freshworks Inc (FRSH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Merck & Co., Inc. — how do they compare? Freshworks Inc trades at $10.61 (market cap $2.93B), while Merck & Co., Inc. trades at $128.51 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 104.2× Freshworks Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | MRK | |
|---|---|---|
Market Cap | $2.93B | $305.29B |
Sector | Technology | Health |
52-Week High | $14.77 | $129.52 |
52-Week Low | $6.88 | $77.60 |
Enterprise Value | $2.19B | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.88, up 3.92% with a bullish technical signal and strong revenue growth from $720M in 2024 to $839M in 2025. The company achieved profitability in 2025 with net income of $184M, reversing prior losses. Recent news highlights AI product launches and a key partnership with Vanquis, while analyst consensus is split evenly between Buy and Hold ratings.
The outlook is positive with accelerating revenue and a path to sustained profitability, though high EV/EBITDA of 51.08 suggests premium valuation. Risks include execution on AI initiatives and competitive pressure in SaaS. Wall Street sees 26-38% upside potential based on price targets, making FRSH an attractive growth story if margins expand as projected.
MRK trades at $127.65, up 5.67% today, reflecting strong momentum. The stock shows a bullish technical signal with moving averages supporting the uptrend. Fundamentally, the company reported robust 2025 results with revenue of $65.01B and net income of $18.25B, and recently announced the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline. Analyst consensus is strongly positive with a $137.30 price target.
The outlook for MRK is favorable, driven by earnings beats, strategic acquisitions, and solid profitability. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. The stock presents a growth opportunity with upside to the consensus target, though investors should monitor integration of new acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
